Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 157


Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy.

Seclén E, Soriano V, González MM, Martín-Carbonero L, Gellermann H, Distel M, Kadus W, Poveda E.

J Infect Dis. 2011 Jul 1;204(1):139-44. doi: 10.1093/infdis/jir218.


The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

Santoro MM, Armenia D, Fabeni L, Santoro M, Gori C, Forbici F, Svicher V, Bertoli A, Dori L, Surdo M, Balestra E, Palamara G, Girardi E, Angarano G, Andreoni M, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF.

Clin Microbiol Infect. 2012 Aug;18(8):E289-98. doi: 10.1111/j.1469-0691.2012.03905.x. Epub 2012 Jun 8.


Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.

Nozza S, Canducci F, Galli L, Cozzi-Lepri A, Capobianchi MR, Ceresola ER, Narciso P, Libertone R, Castelli P, Moioli M, D'Arminio Monforte A, Castagna A; ICONA Foundation.

J Antimicrob Chemother. 2012 May;67(5):1224-7. doi: 10.1093/jac/dkr600. Epub 2012 Jan 31.


The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.

Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G.

Clin Infect Dis. 2008 May 15;46(10):1617-23. doi: 10.1086/587660.


HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil.

Lanca AM, Collares JK, Ferreira JL, Lima DM, Brigido LF, Rodrigues R, Fonseca BA.

Mem Inst Oswaldo Cruz. 2012 Feb;107(1):96-101.


Co-receptor switch during HAART is independent of virological success.

Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, Ladisa N, Tartaglia A, Lagioia A, Angarano G.

J Med Virol. 2009 Dec;81(12):2036-44. doi: 10.1002/jmv.21598.


Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.

Soulié C, Charpentier C, Flandre P, Nino C, Carcelain G, Simon A, Katlama C, Landman R, Brun-Vézinet F, Descamps D, Calvez V, Marcelin AG.

J Med Virol. 2012 Dec;84(12):1853-6. doi: 10.1002/jmv.23362.


Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.


Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.

Wu H, Connick E, Kuritzkes DR, Landay A, Spritzler J, Zhang B, Spear GT, Kessler H, Lederman MM; ACTG 315 Team.

AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1231-40.


HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.

Treviño A, Soriano V, Poveda E, Parra P, Cabezas T, Caballero E, Roc L, Rodríguez C, Eiros JM, Lopez M, De Mendoza C; HIV-2 Spanish Study Group.

J Antimicrob Chemother. 2014 Aug;69(8):2191-4. doi: 10.1093/jac/dku119. Epub 2014 Apr 30.


Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group.

J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 Nov 14.


HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.

Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V.

AIDS. 2007 Oct 18;21(16):2243-5.


Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years.

Briz V, Poveda E, del Mar González M, Martín-Carbonero L, González-González R, Soriano V.

J Antimicrob Chemother. 2008 Feb;61(2):405-10. Epub 2007 Dec 6.


Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.

Ferrer P, Tello M, Montecinos L, Tordecilla R, Rodríguez C, Beltrán C, Guzmán MA, Ferrés M, Pérez CM, Afani A.

J Clin Virol. 2014 Jul;60(3):290-4. doi: 10.1016/j.jcv.2014.04.004. Epub 2014 Apr 15.


Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.


Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance.

de Mendoza C, Rodriguez C, García F, Eiros JM, Ruíz L, Caballero E, Aguilera A, Leiva P, Colomina J, Gutierrez F, del Romero J, Aguero J, Soriano V; Spanish HIV Seroconverter Study Group.

J Antimicrob Chemother. 2007 Apr;59(4):698-704. Epub 2007 Feb 27.


Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.


Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team.

AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.


Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M.

Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):729-35.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk